Efficacy and safety of adjuvant CDK4/6 inhibitors in hormone receptor-positive, HER2-negative early breast cancer: Updated evidence from a systematic review and meta-analysis.
IntroductionThe long-term survival impact of adding CDK4/6 inhibitors to adjuvant endocrine therapy for hormone receptor-positive, HER2-negative (HR+/HER2-) early breast cancer remains a subject of active evaluation. We performed an updated meta-analysis incorporating the mature efficacy and survival data to comprehens...